Clinical Trial

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Study acronym: RIOT2
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-08-23; most recent amendment 2025-05-19.
Status change: Not Yet Recruiting → Recruiting 2024-01-30
Trial Details
NCT Number NCT06016179
Lead Sponsor Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Conditions Malignant Pleural Effusion, Malignant Ascites
Enrollment 12 participants
Start Date 2024-01-30
Primary Completion 2026-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-22